Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
With best-selling medicines for type 2 diabetes and obesity in hand, Novo Nordisk (NYSE: NVO) isn’t content to let the chips fall where they may when it comes to patients having access to Ozempic and Wegovy. Thanks to the two drugs becoming a social phenomenon in the developed wo
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1917868586-d64880817bca4098bc8be36bbd17a4e9.jpg "Should You Trade Options on Spot Bitcoin ETFs?")